Diagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory
|
|
- Jacob Mathews
- 6 years ago
- Views:
Transcription
1 Diagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc.
2 Learning Objectives Compare traditional myeloma testing methods with current recommended protocols and describe how kappa & lambda free light chain analysis plays a key role. Discuss the updated IMWG criteria for diagnosis of Multiple Myeloma and new recommendations for inclusion in routine practice. Explain why it is necessary to monitor both intact immunoglobulin paraprotein and serum free light chains in multiple myeloma.
3 Disclaimer Some of the subject matter and data contained or addressed in this session may involve off-label or forward-looking use of Freelite
4 In This Talk Introduction Depth of Response Multiple Myeloma Biology of FLCs Monitoring with Freelite Updated MM Diagnostic Criteria
5 Multiple Myeloma A Cancer of the Plasma Cells in the Bone Marrow Multiple Myeloma: Abnormal bone marrow with sheets of plasma cells 1% vs up to 90%
6 Definition of MGUS, SMM and Symptomatic Multiple Myeloma Ghobrial and Landgren. Blood, Oct 2014, prepub.online; doi: /blood
7 Plasma cells secrete intact antibody and free light chains Light Chain Heavy Chain Kappa, k Lambda, l Kappa releasing Lambda releasing
8 Monoclonal gammopathies Disorders associated with monoclonal proteins Asymptomatic e.g. MGUS Malignant e.g. MM, AL amyloidosis
9 Any type of Multiple Myeloma can express free light chains Intact Immunoglobulin 80% Light chain only 15-20% Nonsecretory 1-2% 89% 100% 68% Abnormal k/l sflc ratio
10 Traditional tools for detecting M-proteins Serum protein electrophoresis (SPE) Monoclonal protein in γ region Immunofixation electrophoresis (IFE) IgGl monoclonal protein
11 Sensitivity of SPE at diagnosis Multiple myeloma AL amyloidosis 88% 66% Intact immunoglobulin Light chain Nonsecretory 97% 61% 0% Katzmann Clin Chem 2009;55: Jeong CCLM 2013;51:e187-9
12 Laboratory investigation for monoclonal proteins associated with multiple myeloma g/l Intact Ig MM Serum SPE + electrophoresis Serum Freelite mg/l Light Chain MM Urine Serum Freelite electrophoresis
13 Freelite immunoassay: polyclonal antisera to monoclonal proteins Heavy chain k FLC Light chain Hidden surface l FLC Exposed surface
14 Freelite immunoassay: polyclonal antisera to monoclonal proteins k FLC k FLC l FLC mg/l mg/l Exposed surface k/l sflc ratio Range = Median = 0.6 l FLC Katzmann Clin Chem 2002;48:
15 Interpretation of Free Light Chain Results k l k/l Ratio mg/l mg/l Normal Normal or Decreased Monoclonal k Normal or Decreased Monoclonal l Normal or Slightly Increased Normal Renal Impairment Polyclonal Gammopathy Jagannath Clin Lymphoma Myeloma, 7(8):518-23; 2007
16 Higher risk of malignant plasma cell disorder is associated with more extreme k/l ratio Lambda secretor Normal Kappa Secretor k/l ratio k/l ratio : Risk : Likely Possible Very Low Inconclusive Possible Likely Katzmann J, Clin Chem : 1437 Vermeersch Clin Chem Acta : 54-58
17 Light chain concentration (mg/l) Analytical sensitivity Freelite is more sensitive than electrophoresis SPE CZE sife 10 Normal range in serum 1 Freelite
18 SPE alone is insensitive at diagnosis Screening algorithm Diagnostic sensitivity (%) SPE sife + uife SPE + sflc MM AL MM AL MM AL Testing with Freelite in addition to SPE improves detection rates and eliminates the reliance on urine testing Katzmann Clin Chem 2009;55:
19 Use of the FLC assay has significantly changed the way that patients with AL amyloidosis are diagnosed and monitored..the serum FLC assay is critical for evaluating patients with AL, as many patients lack a measurable circulating intact immunoglobulin. Comenzo Leukemia 2012;26:
20 Updated criteria for diagnosis of myeloma Clonal bone marrow plasma cells 10% or biopsy-proven bony or extramedullary plasmacytoma and one/more myeloma defining events: Any one or more biomarkers of malignancy (SLiM) Related end organ damage (CRAB) Clonal bone marrow plasma cell percentage 60% (Sixty %) Involved/uninvolved serum Free Light Chain ratio 100* >1 focal lesion on MRI studies HyperCalcemia Renal insufficiency Anemia Bone lesions Rajkumar Lancet Oncol 2014;15:e538-e548 Reprinted from Lancet Oncology, 2014, with permission from Elsevier. *By Freelite iflc must be 100 mg/l
21 Implication The same characteristics that make Freelite an effective addition to multiple myeloma diagnosis make it an important element in monitoring
22 Term iflc (involved) uflc (uninvolved) k/λ sflc ratio Involved/uninvolved sflc ratio dflc (difference) FLC definitions Use Tumor load / response to therapy Polyclonal light chain, may be influenced by renal function Clonality and confirmation of response Define biomarker of malignancy Tumor load / response to therapy For a patient with monoclonal l sflc l sflc k sflc k sflc / λ sflc l sflc / k sflc l sflc - k sflc
23 dflc provides better assessment of response to therapy k sflc (mg/l) l sflc (mg/l) k/l sflc ratio Normal range dflc (mg/l) Baseline st time point k/l sflc ratio The same pre- and post-therapy Therapy failure? iflc or dflc 90% reduction Therapy successful
24 dflc less affected by renal impairment k sflc l sflc k/l sflc (mg/l) (mg/l) ratio Normal range dflc (mg/l) Baseline st time point Renal impairment develops 2 nd time point rd time point k/l sflc ratio Not recommended for serial monitoring
25 for serial measurements, either the involved FLC or the difference between the involved and uninvolved (dflc) should be used. Dispenzieri Leukemia 2009;23:
26 Summary of IMWG recommendations Diagnosis k/l sflc ratio involved/ uninvolved sflc ratio iflc or dflc Monitoring k/l sflc ratio Define clonality Define biomarker of malignancy Dispenzieri Leukemia 2009;23: Rajkumar Lancet Oncology 2014;15:e538-e548 Assess response Define scr
27 Short half-life Depth of response Why monitor with Freelite Enhanced sensitivity Clonal change Residual disease / Early relapse
28 The short half-life of sflcs allows rapid response assessment 0 24 hour 1 week 1 month 3 months κ FLC λ FLC 2-6 hours IgA IgM 5-7 days IgG ~21 days
29 k sflc (mg/l) IgG (SPE, g/l) Change in iflc demonstrates response to therapy more rapidly than SPE Rx 1 Rx 2 Rx 3 0.1% Plasma cells k sflc Monoclonal IgG Time from Presentation (days) Courtesy of G. Mead
30 Short half-life Depth of response Why monitor with Freelite Enhanced sensitivity Clonal change Residual disease / Early relapse
31 Light chain concentration (mg/l) Analytical sensitivity Freelite is ~ 10-fold more sensitive than uife SPE CZE sife 10 Normal range in serum UPE uife 1 Freelite
32 FLCs are filtered, reabsorbed and catabolised in the kidney FLCs produced 0.5-1g/day reabsorptive capacity 10-30g/day Urine FLC levels are a function of production minus reabsorption
33 Urine κ BJP (g/24hr) k Urine BJP (g/24h) Serum k sflc κ FLC (mg/l) (mg/l) Urine κ BJP (g/24hr) k Urine BJP (g/24h) Serum k sflc κ FLC (mg/l) (mg/l) Urine λ BJP (g/24hr) l Urine BJP (g/24h) Serum l sflc λ FLC (mg/l) (mg/l) Urine κ BJP (g/24hr) k Urine BJP (g/24h) Serum k sflc κ FLC (mg/l) (mg/l) Freelite provides equivalent or superior information to urine BJP HDC, ASCT Time Time (months) Thalidomide Time (months) sflc concentration urine BJP (24hr) Severe osteolytic lesions HDC, ASCT Time Time (months) Time (months) 0 Alyanakian Am J Hematol 2004;75: Wiley Periodicals, Inc.
34 dflc (mg/l) UPE densitometry (mg/24h) dflc (mg/l) UPE densitometery (mg/24h) Freelite provides equivalent or superior information to urine BJP A uife Presentation 1 2Cycle 2 3Cycle 4 4 ASCT 5 B dflc ubjp uife - - dflc ubjp sife Cycle 2 G A M κ λ G A M κ λ 1 0Presentation 1 Cycle 2 2 Cycle 3 4 4ASCT 5 Dejoie Haematologica 2016;101: T. Dejoie, et al., Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma. Haematologica 2016;101:361 0
35 Three advantages of serum Freelite vs. urine electrophoresis Freelite 10 X more sensitive than UPE/uIFE FLCs are not always found in urine Renal metabolism Inadequate sample Analytical sensitivity Urine compliance Freelite vs. urine analysis
36 Short half-life Depth of response Why monitor with Freelite Enhanced sensitivity Clonal change Residual disease / Early relapse
37 sflc detects relapse earlier than IFE Mosbauer Haematologica 2007;92: U. Mosbauer, et al., Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation. Haematologica 2007;92:275
38 Abnormal FLC ratios indicate residual disease in Intact Ig Multiple Myeloma 31 IFE negative IIMM patients Reid Bone Marrow Transplant 2004;33:623a
39 Abnormal FLC ratios indicate residual disease in Light Chain Multiple Myeloma 35 IFE negative LCMM patients + Normal sera CR Normal ratio CR Abnormal ratio Reid Bone Marrow Transplant 2004;33:623a Reid Clin Chem 2004;50:C34a
40 Short half-life Depth of response Why monitor with Freelite Enhanced sensitivity Clonal change Residual disease / Early relapse
41 Why do we need multiple tools to monitor?
42 k sflc (mg/l) sflcs and intact Igs are independent tumor markers n=164 IgGk MM R 2 = IgGk (g/l) IFM data courtesy of H. Avet-Loiseau κflc measured using Freelite IgGκ measured using Hevylite
43 At diagnosis, myeloma patients exhibit clonal heterogeneity IgGk multiple myeloma IgGk k FLC dual populations are an example of intra-clonal heterogeneity in monoclonal gammopathies Ayliffe J Clin Pathol 2012;65: Ayliffe Haematologica 2007;92: M. Ayliffe, et al., Demonstration of changes in plasma cell subsets in patients with multiple myeloma. Haematologica 2007;92:1136
44 Sensitive techniques can identify clonal change Clonal populations change during therapy 5 unique clones at diagnosis Adapted from Keats Blood 2012;120: Republished with permission of the American Society of Hematology, permission conveyed through Copyright Clearance Center, Inc.
45 At relapse Clonal diversity at relapse Monoclonal protein at diagnosis FLC & intact Ig FLC only Intact Ig only 22% 68% 10% 100% 22% 40% 17% 38% 83% (n =126) 44% patients changed their monoclonal protein type Adapted from Zamarin Bone Marrow Transplant 2012;48:
46 Light chain escape rising monoclonal free light chain production at relapse without increased monoclonal intact immunoglobulin Courtesy of Christie Hospital, UK
47 Light chain escape 6.5% 19.9% IgG IgA Only ½ of LCE patients were ubjp positive n=520 pts Brioli Blood 2014;123:3414-9
48 Short half-life Depth of response Why monitor with Freelite Enhanced sensitivity Clonal change Residual disease / Early relapse
49 IMWG Defining Response For patients with measurable disease by electrophoresis Complete response (CR) Stringent complete response (scr) Negative serum/urine IFE BM plasma cells 5% Negative serum/urine IFE Absence of clonal cells in BM Normal sflc ratio Rajkumar Blood 2011;117:4691-5
50 Overall Survival (Probability) Attaining scr improves survival scr improved overall survival Kapoor J Clin Oncol 2013;31: Originally published by the American Society of Clinical Oncology. Time since transplantation (years)
51 Overall survival (%) Median survival from relapse (months) Relapse with FLC indicates poorer survival FLC & Intact Ig FLC escape Intact Ig only p= Time (months) Brioli Blood 2014;123: Republished with permission of the American Society of Hematology, permission conveyed through Copyright Clearance Center, Inc.
52 Progression free survival Overall Survival Normalization of sflc ratio improves survival across all response levels Progression Free Survival Normal k/l sflc ratio Abnormal k/l sflc ratio Overall Survival Follow up from diagnosis (months) 29 vs. 16 months (P <.001) Follow up from diagnosis (months) 91 vs. 58 months (P <.001) Moustafa Leukemia 2015;29: Reprinted by permission from Macmillan Publishers Ltd: Leukemia, 2009.
53 Summary Freelite enhances MM monitoring Rapid evaluation of response Enhanced sensitivity compared to SPE and UPE Detects residual disease and early relapse Detects clonal change when combined with monoclonal intact Ig measurements Depth of sflc response correlates with survival
54 Any Questions? (206)
Diagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory
Diagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc. Learning Objectives Compare traditional
More informationABC of laboratory techniques for diagnosis and follow-up of monoclonal gammopathies. An Hendrickx MSc. Scientific Advisor
ABC of laboratory techniques for diagnosis and follow-up of monoclonal gammopathies An Hendrickx MSc. Scientific Advisor In this talk introduction biology of free light chains laboratorium investigation
More informationMeasuring Myeloma in the LAB. BL Ferry Clinical Lead Sept 15 th 2014
Measuring Myeloma in the LAB BL Ferry Clinical Lead Sept 15 th 2014 Oxford Immunology Laboratory Clinical Immunology Churchill WHAT DO WE MEASURE AND HOW? Clinical Immunology Churchill Serum proteins Proteins
More informationFreelite & Hevylite. Together Freelite & Hevylite catch more monoclonal gammopathy patients. The Specialist Protein Company
Freelite & Hevylite Together Freelite & Hevylite catch more monoclonal gammopathy patients The Specialist Protein Company Freelite The Freelite assay is composed of two sensitive and specific polyclonal
More informationSerum heavy-light chain analysis (Hevylite): clinical applications for multiple myeloma
Serum heavy-light chain analysis (Hevylite): clinical applications for multiple myeloma Kelly Endean PhD Scientific Affairs Manager, The Binding Site Focus of this talk An introduction to heavy-light chain
More informationFreelite & Hevylite. Together Freelite & Hevylite provide optimal detection of monoclonal gammopathies
Freelite & Hevylite Together Freelite & Hevylite provide optimal detection of monoclonal gammopathies Monoclonal Gammopathy Monoclonal gammopathies are diseases of the bone marrow and are associated with
More informationApplicazioni della misura delle Free Light Chain nella pratica clinica. Maria Teresa Petrucci
Applicazioni della misura delle Free Light Chain nella pratica clinica Maria Teresa Petrucci Serum free light chain immunoassay Heavy chain Kappa Light chain Hidden surface Lambda Exposed surface Serum
More informationSerum Free Light Chain Assays
Freelite Serum Free Light Chain Assays An aid to the diagnosis of: Light Chain (Bence Jones) Multiple Myeloma (LCMM) Nonsecretory Multiple Myeloma (NSMM) AL amyloidosis Light Chain Deposition Disease (LCDD)
More informationWhat do you do, with an M protein?
What do you do, with an M protein? Cancer Day for Primary Care Emily Rimmer MD FRCPC January 31, 2014 emily.rimmer@cancercare.mb.ca Disclosure of Potential for Conflict of Interest Name of presenter: Emily
More informationGuidelines for the diagnosis of Multiple Myeloma Ass.lec.: Dr. Karam T. Agha M.Sc.Pathology
Guidelines for the diagnosis of Multiple Myeloma 2014 By:British Committee for Standards in Haematology (BCSH) Ass.lec.: Dr. Karam T. Agha M.Sc.Pathology Diagnosis, prognostic factors and disease monitoring
More informationHevylite: New strategies for Diagnosis, Monitoring and Prognosis of monoclonal gammopathies
Hevylite: New strategies for Diagnosis, Monitoring and Prognosis of monoclonal gammopathies AR Bradwell. University of Birmingham and Binding Site Ltd How good are tests for monoclonal monoclonal proteins?
More informationImmunoglobulin / free light chain ratio
Immunoglobulin / free light chain ratio 1 1 2 Kiyotaka FUJITA Katsunori TAKAHASHI Ikunosuke SAKURABAYASHI FLC IgG, IgA, IgM, IgD, IgE 5 1 1 H 1 L H,,,, L 2 monoclonal immunoglobulinemia : M L L H 40 H
More informationFreelite for Measurement of Urine-Free Light Chains in Monoclonal Gammopathies
Freelite for Measurement of Urine-Free Light Chains in Monoclonal Gammopathies Montgomery Lobe, MD, and Donald Pasquale, MD Abstract Monoclonal gammopathies are characterized by production of monoclonal
More informationJune Laboratory Evaluation of Plasma Cell Neoplasms Stan McCormick, MD
June 2011 Laboratory Evaluation of Plasma Cell Neoplasms Stan McCormick, MD In this issue we review the laboratory work up of patients suspected of having a plasma cell neoplasm. As the range in clinical
More informationIntact immunoglobulin heavy/light chain paired assays
Intact immunoglobulin heavy/light chain paired assays Stephen Harding 1, Philip Young 1, Marina Di Fazio 2, Richard Hughes 1 1Research and Development, The Binding Site Group, Birmingham, UK 2Scientific
More informationAssessment of Serum Free Light Chain Assays for Plasma Cell Disorder Screening in a Veterans Affairs Population
Available online at www.annclinlabsci.org Annals of Clinical & Laboratory Science, vol 36, no. 2, 2006 157 Assessment of Serum Free Light Chain Assays for Plasma Cell Disorder Screening in a Veterans Affairs
More informationDIAGNOSIS OF MYELOMA BASED ON THE 2014 INTERNATIONAL MYELOMA WORKING GROUP
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Majalah Patologi Klinik Indonesia dan Laboratorium Medik Page 196 2018 March; 24(2): 196-200 p-issn 0854-4263 e-issn 2477-4685 Available
More informationLaboratories and the New IMWG Myeloma Guidelines
Laboratories and the New IMWG Myeloma Guidelines David F. Keren, M.D. Professor of Pathology Division Director, Clinical Pathology The University of Michigan dkeren@med.umich.edu Speaker Disclosure In
More informationUnderstanding Lab Values in Multiple Myeloma
Understanding Lab Values in Multiple Myeloma A reference guide to the common laboratory tests used in the diagnosis and monitoring of multiple myeloma Differential Diagnosis Multiple Myeloma (MM) Is a
More informationElevated Immunoglobulins and Paraproteins
Elevated Immunoglobulins and Paraproteins NWL Pathology GP Study Afternoon Thursday 19 th October 2017 Dr Aristeidis Chaidos Consultant Haematologist and Honorary Senior Clinical Lecturer Hammersmith Hospital,
More informationSmoldering Multiple Myeloma
Smoldering Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationSouthern Derbyshire Shared Care Pathology Guidelines. Diagnosis and Management of Myeloma
Southern Derbyshire Shared Care Pathology Guidelines Diagnosis and Management of Myeloma When to screen for Myeloma and related disorders Not recommended to screen the normal population Clinical Symptoms,
More informationLaboratory Persistence and Clinical Progression of Small Monoclonal Abnormalities
Immunopathology / Persistence of IFE MGUS Laboratory Persistence and Clinical Progression of Small Monoclonal Abnormalities David L. Murray, MD, PhD, 1 Justin L. Seningen, MD, 1 Angela Dispenzieri, MD,
More informationDiagnosis and Current Standard Treatments for Multiple Myeloma. Natalie S. Callander, M.D Professor of Medicine
Diagnosis and Current Standard Treatments for Multiple Myeloma Natalie S. Callander, M.D Professor of Medicine Goals Introduce and/or compliment understanding of plasma cell disorders-mgus, SMM and symptomatic
More informationSerum Free Light Chain (FLC) Measurement Can Aid Capillary Zone Electrophoresis in Detecting Subtle FLC-Producing M Proteins
Immunopathology / DETECTING SUBTLE FLC-PRODUCING M PROTEINS Serum Free Light Chain (FLC) Measurement Can Aid Capillary Zone Electrophoresis in Detecting Subtle FLC-Producing M Proteins Nasir A, Bakshi,
More informationSerum Free Light Chain Analysis
Serum Free Light Chain Analysis Rajeevan Selvaratnam, Jing Cao and Amy B. Karger Introduction In healthy individuals, plasma cells originating from the bone marrow produce immunoglobulin molecules composed
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm Myeloma 101: Disease Overview Hans Lee, MD Assistant Professor Department of Lymphoma/Myeloma University of Texas MD Anderson Cancer Center No Disclosures
More informationserum FLC concentration was available twice as often as a measurable urine M-spike American Association for Clinical Chemistry
Clinical Chemistry 57:12 1687 1692 (2011) Clinical Immunology Long-Term Biological Variation of Serum Protein Electrophoresis M-Spike, Urine M-Spike, and Monoclonal Serum Free Light Chain Quantification:
More informationبسم اهلل الرمحن الرحيم
بسم اهلل الرمحن الرحيم Definition Multiple myeloma is a neoplastic plasma cell dyscrasia (PCD) that generally produced a monoclonal immunoglobulin protein, characterized by a clinical pentad: (a) anemia;
More informationSerum Free Light Chain (FLC) Analysis: A Guiding Light in Monoclonal Gammopathy Management
Serum Free Light Chain (FLC) Analysis: A Guiding Light in Monoclonal Gammopathy Management Ellen L. Jenner, 1 Josie A.R. Evans, 1 and Stephen J. Harding 1 * Background: Monoclonal free light chains (FLCs)
More informationEffective Health Care Program
Comparative Effectiveness Review Number 73 Effective Health Care Program Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias Executive Summary Background
More informationRestrooms Cell phones on silent/vibrate. Refreshments. Patient resource materials
Restrooms Cell phones on silent/vibrate Refreshments Patient resource materials This presentation should not replace discussions with your healthcare provider, but seeks to provide information and resources
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mateos M-V, Hernández M-T, Giraldo P, et al. Lenalidomide plus
More informationMyeloma Primary Care. Dr R Lovell Feb 2015
Myeloma Primary Care Dr R Lovell Feb 2015 Aims Balance of pathophysiology and cases Explain diagnostic changes (minimal) Staging UK influence Autologous stem cell transplants Primary care myeloma problems
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Transformed Pre- Ig Surface Surface Secreted B- ALL Macroglobulinemia Myeloma
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationSerum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma-Cell Dyscrasias
DRAFT Comparative Effectiveness Review Number xx Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma-Cell Dyscrasias Prepared for: Agency for Healthcare Research and
More informationUrine Protein Electrophoresis and Immunoelectrophoresis Using Unconcentrated or Minimally Concentrated Urine Samples
Immunopathology / Electrophoresis of Unconcentrated Urine Samples Urine Protein Electrophoresis and Immunoelectrophoresis Using Unconcentrated or Minimally Concentrated Urine Samples Anja C. Roden, MD,
More informationParameswaran Hari Medical College of Wisconsin Milwaukee
Multiple Myeloma Linking the clinical course to report forms Parameswaran Hari Medical College of Wisconsin Milwaukee 45,000 Annual Numbers of Blood and Marrow Transplants Worldwide 1970-2003 40,000 Number
More informationDiagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy
Hutchison et al. BMC Clinical Pathology 2012, 12:12 TECHNICAL ADVANCE Open Access Diagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy
More informationHandout for lecture on plasma cell neoplasms presented by Rob McKenna
Handout for lecture on plasma cell neoplasms presented by Rob McKenna The following slides represent a near final version of the presentation that will be given in Maui, January 23,2018. Minor changes
More informationCurrent Issues in Pharmacy and Medical Sciences. journal homepage:
Curr. Issues Pharm. Med. Sci., Vol., No., Pages 5- Current Issues in Pharmacy and Medical Sciences Formerly ANNALES UNIVERSITATIS MARIAE CURIE-SKLODOWSKA, SECTIO DDD, PHARMACIA journal homepage: http://www.curipms.umlub.pl/
More informationCurrent Issues in Pharmacy and Medical Sciences. journal homepage:
Curr. Issues Pharm. Med. Sci., Vol., No., Pages 5- Current Issues in Pharmacy and Medical Sciences Formerly ANNALES UNIVERSITATIS MARIAE CURIE-SKLODOWSKA, SECTIO DDD, PHARMACIA journal homepage: http://www.curipms.umlub.pl/
More informationDiagnosis and staging
Chapter 2 Diagnosis and staging Carlos Fernández de Larrea and Joan Bladé Diagnostic criteria Multiple myeloma (MM) is a plasma cell disorder characterized by a clonal proliferation of cells producing
More informationDiagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder
research paper Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder Pieter Vermeersch, 1 * Lieve Van Hoovels, 1 * Michel Delforge, 2 Godelieve
More informatione-issn X Modern Medical Laboratory Journal
Review Article Mod Med Lab J. 2018; 2(1):20-28 e-issn 2371-770X Modern Medical Laboratory Journal DOI: Serum Free Light-chain Assay for the Diagnosis, Management, and Prognosis of Multiple Myeloma Nawal
More informationMultiple myeloma (MM) & related disorders
Multiple myeloma (MM) & related disorders Plasma cell neoplasms Six major variants: (1) Multiple myeloma (2) Solitary plasmacytoma (3) Lymphoplasmacytic lymphoma They secrete a single complete or partial
More informationChange Summary - Form 2116 (R3) 1 of 6
Change Summary - Form 2116 (R3) 1 of 6 Form Question Number (r3) Question Text Change Type Description New Text Previous Text Previous Question Number (r2) 2116 Today's date: Removed "Today's date:" was
More informationMultiple Myeloma Highlights From the 2015 ASCO Annual Meeting and the 20 th Congress of EHA
Multiple Myeloma Highlights From the 2015 ASCO Annual Meeting and the 20 th Congress of EHA July 13, 2015 Welcome and Introductions Anne Quinn Young, MPH Multiple Myeloma Research Foundation Norwalk, CT
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Pr e- Transformed Ig Su rf ace Su rf ace Secre ted Myelom a
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pr e- B-ce ll B-ce ll Transformed B-ce ll Plasma cell Ig Su rf ace Su rf ace Secre ted Major malignant
More informationEDUCATIONAL COMMENTARY LABORATORY EVALUATION OF IMMUNOPROLIFERATIVE DISORDERS
Commentary provided by: Louann W. Lawrence, Dr.PH, MLS (ASCP) Professor Emeritus, Retired Louisiana State University Health Sciences Center New Orleans, LA EDUCATIONAL COMMENTARY LABORATORY EVALUATION
More informationThis Infosheet explains what Monoclonal Gammopathy of Undetermined Significance (MGUS) is and how it is diagnosed and managed.
MGUS This Infosheet explains what Monoclonal Gammopathy of Undetermined Significance (MGUS) is and how it is diagnosed and managed. What is MGUS? Monoclonal gammopathy of undetermined significance, or
More informationBrian GM Durie. Black Swan Research Initiative (BSRI) Purpose
Black Swan Research Initiative Brian GM Durie Saturday August 22, 2015 1 Black Swan Research Initiative (BSRI) Purpose The Black Swan Research Initiative (BSRI) is a global collaborative approach Which
More informationacute leukemia precursor chronic leukemia lymphoma
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated t d Pre- B-cell B-cell Ig Surface Transformed B-cell Surface Plasma cell Secreted Major malignant counterpart
More informationCASE REPORT AND REVIEW OF THE LITERATURE
Page 76 / SA ORTHOPAEDIC JOURNAL Summer 2009 C ASE R EPORT AND R EVIEW OF THE L ITERATURE Low-secretory multiple myeloma HF Visser MBChB(Pret) Senior Registrar, Department Orthopaedic Surgery, University
More informationSmouldering myeloma. Myeloma Infosheet Series. Other related conditions. Infoline:
Smouldering myeloma This Infosheet provides information on what smouldering myeloma is, how it is diagnosed, what the treatment is and will explain the link between smouldering myeloma and active myeloma.
More informationWG-ICQA Harmonisation of Interpretive Commenting EQA
WG-ICQA Harmonisation of Interpretive Commenting EQA WG-ICQA Subgroup: Harmonisation of reporting of protein electrophoresis and serum FLC, and quantification of small monoclonal proteins Improved patient
More informationSharply Increased Serum Free Light-Chain Concentrations after Treatment for Multiple Myeloma
Clinical Chemistry 56:1 16 20 (2010) Clinical Case Study Sharply Increased Serum Free Light-Chain Concentrations after Treatment for Multiple Myeloma Kazunori Murata, 1 Raynell J. Clark, 1 Karen S. Lockington,
More informationCase Report Serum Free Light Chain Only Myeloma with Cytoplasmic IgM
Hindawi Publishing Corporation Case Reports in Hematology Volume 2014, Article ID 676913, 5 pages http://dx.doi.org/10.1155/2014/676913 Case Report Serum Free Light Chain Only Myeloma with Cytoplasmic
More informationManagement of AKI in Myeloma: Novel Approaches Dr Colin A Hutchison
Management of AKI in Myeloma: Novel Approaches Dr Colin A Hutchison Consultant Nephrologist, Hawke s Bay DHB, NZ Senior Lecturer, University of Birmingham, Birmingham, UK Why are nephrologists interested
More informationCytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels
Published Ahead of Print on February 1, 2018, as doi:10.3324/haematol.2017.184226. Copyright 2018 Ferrata Storti Foundation. Cytogenetic aberrations in multiple myeloma are associated with shifts in serum
More informationUnderstanding MGUS and Smoldering Multiple Myeloma
Multiple Myeloma Cancer of the Bone Marrow Understanding MGUS and Smoldering Multiple Myeloma u-mgus+smm_en_2017_i1 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE
More informationPerformance of the Sebia CAPILLARYS 2 for Detection and Immunotyping of Serum Monoclonal Paraproteins
Immunopathology / SEBIA CAPILLARYS 2 PARAPROTEIN DETECTION Performance of the Sebia CAPILLARYS 2 for Detection and Immunotyping of Serum Monoclonal Paraproteins Zhaohai Yang, MD, PhD, Keith Harrison, MD,
More informationReport of Survey conducted by IFCC WG Harmonisation of Interpretive Commenting EQA (WG-ICQA) subgroup:
Report of Survey conducted by IFCC WG Harmonisation of Interpretive Commenting EQA (WG-ICQA) subgroup: Results of an international survey of the reporting of protein electrophoresis and serum free light
More informationJerry A. Katzmann, 1* Raynell J. Clark, 1 Roshini S. Abraham, 1 Sandra Bryant, 1 James F. Lymp, 1 Arthur R. Bradwell, 2 and Robert A. Kyle 1.
Clinical Chemistry 48:9 1437 1444 (2002) Enzymes and Protein Markers Serum Reference Intervals and Diagnostic Ranges for Free and Free Immunoglobulin Light Chains: Relative Sensitivity for Detection of
More informationSerum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio
Elmer ress Original Article J Clin Med Res. 2017;9(1):46-57 Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio Gurmukh
More informationdiag.of gammop Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS
laboratory diag.of gammop Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS Sarrafnejad@tums.ac.ir Arne Wilhelm Kaurin Tiselius Nobel Prize for Chemistry (1948) Electrophoresis ٤ After
More informationSalvage Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma
Salvage Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Arnon Nagler, M.D., M.Sc Director Hematology Division BMT and Cord Blood Bank Chair Israeli BMT Association Chaim Sheba Medical Center,
More informationMonoclonal gammopathies overview and categorization
Clin Chem Lab Med 2016; 54(6): 907 919 Review Maria A.V. Willrich* and Jerry A. Katzmann Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias
More informationAnalytically coherent
ZO M OCTOBER 2017 N 7 sebia FLC Free light chain testing coherent with electrophoretic methods Analytically coherent SPE: 3.1 g/l FLC Nephelometry: 32.2 g/l FLC ELISA: 3.1 g/l Principle The sebia FLC Kappa
More informationThe Importance of Establishing Baseline Disease Characteristics in Myeloma Diagnosis and Management
I am Dr. Brian Durie at Cedars Sinai Medical Center, Los Angeles. I am also chairman of the International Myeloma Foundation, and I am very pleased today to be participating in this program with my friend
More informationRecommendations For Serum Free Light Chains (SFLC) Measurement In Routine Laboratories
ROYAL PRINCE ALFRED HOSPITAL A tradition of excellence since 1882 Recommendations For Serum Free Light Chains (SFLC) Measurement In Routine Laboratories Louise Wienholt Laboratory Manager Royal Prince
More informationHot Topic. Disclosures. None
Hot Topic Multiple Myeloma Testing at Mayo Medical Laboratories HOT TOPIC / 2017 MFMER 1 Our speaker for this program is Dragan Jevremovic, MD, PhD Assistant Professor, Division of Hematopathology at Mayo
More informationSerum free light chain and Hevylite analyses in the diagnosis, monitoring and prognosis of B cell disorders
Klin. Biochem. Metab., 18 (39), 2010, No. 2, p. 56 61. Serum free light chain and Hevylite analyses in the diagnosis, monitoring and prognosis of B cell disorders Legg A. 1, Harding S. 1, Hughes R. G.
More informationIgA Kappa/IgA Lambda Heavy/Light Chain Assessment in the Management of Patients With IgA Myeloma
Original Article IgA Kappa/IgA Lambda Heavy/Light Chain Assessment in the Management of Patients With IgA Myeloma Eileen M. Boyle, MD 1 ; Guillemette Fouquet, MD 1 ;Stephanie Guidez, MD 1 ; Sarah Bonnet,
More informationThe New England Journal of Medicine A LONG-TERM STUDY OF PROGNOSIS IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE. Patients
A LONG-TERM STUDY OF PROGNOSIS IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE ROBERT A. KYLE, M.D., TERRY M. THERNEAU, PH.D., S. VINCENT RAJKUMAR, M.D., JANICE R. OFFORD, B.S., DIRK R. LARSON, M.S.,
More informationMultiple Myeloma Patient Handbook
Myeloma Canada Mailing Address: Myeloma Canada 1255 Trans-Canada Highway Suite 160 Dorval, QC H9P 2V4 Telephone: Toll-free: 1-888-798-5771 E-mail: contact@myeloma.ca Multiple Myeloma Patient Handbook Website:
More informationFive-Year Follow-up Study of Monoclonal Gammopathy of Undetermined Significance in a Korean Elderly Urban Cohort
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2014 Aug 29 [Epub ahead of print] Original Article http://dx.doi.org/10.4143/crt.2013.262 Open Access Five-Year Follow-up Study of Monoclonal Gammopathy
More informationDetection of intracellular IgD using flow cytometry could be a novel and supplementary method to diagnose IgD multiple myeloma
Wang et al. BMC Cancer (2018) 18:650 https://doi.org/10.1186/s12885-018-4562-8 RESEARCH ARTICLE Open Access Detection of intracellular IgD using flow cytometry could be a novel and supplementary method
More informationEvaluation of Sebia s Capillarys 2 flex-piercing system in. level monoclonal protein in serum and urine of patients
Peer reviewed ORIGINAL ARTICLE Evaluation of Sebia s Capillarys 2 flex-piercing system in comparison with Hydrasys gel system, in identifying low level monoclonal protein in serum and urine of patients
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation in the Era of Novel Therapies Larry Anderson, MD, PhD Multiple Myeloma and Stem Cell Transplant
More informationIndex. Quinzanini, M. Departments of Rheumatology, Immunology & Allergology, Azienda Ospedaliera Spedali Civili, Brescia, Italy
Poster from the Congress EUROMEDLAB Barcelona, 1-5 June 2003 15 th IFCC-FESCC European Congress of Clinical Chemistry and Laboratory Medicine 22 nd National Congress of the Spanish Society of Clinical
More informationScreening Panels for Detection of Monoclonal Gammopathies
Clinical Chemistry 55:8 1517 1522 (2009) Clinical Immunology Screening Panels for Detection of Monoclonal Gammopathies Jerry A. Katzmann, 1,2* Robert A. Kyle, 1,2 Joanne Benson, 3 Dirk R. Larson, 3 Melissa
More informationIntroduction. Point. Keywords: electrophoresis; Hevylite; IgA; immunoglobulin; monoclonal protein.
Clin Chem Lab Med 2015; aop Point Josie A.R. Evans*, Ellen L. Jenner, Hugh D. Carr Smith, Oscar Berlanga and Stephen J. Harding Quantification of β-region IgA monoclonal proteins shouldwe include immunochemical
More informationPrognostic utility of intact immunoglobulin Ig 0 k/ig 0 l ratios in multiple myeloma patients
Leukemia (2013) 27, 202 207 & 2013 Macmillan Publishers Limited All rights reserved 0887-6924/13 www.nature.com/leu ORIGINAL ARTICLE Prognostic utility of intact immunoglobulin Ig 0 k/ig 0 l ratios in
More informationMonitoring Multiple Myeloma
Monitoring Multiple Myeloma Kyle A. Udd, BS, Tanya M. Spektor, PhD, and James R. Berenson, MD Mr Udd is a medical research data analyst at the Institute for Myeloma & Bone Cancer Research in West Hollywood,
More informationClinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
T h e n e w e ng l a nd j o u r na l o f m e dic i n e original article Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma Robert A. Kyle, M.D., Ellen D. Remstein, M.D., Terry
More informationFive-Year Follow-up Study of Monoclonal Gammopathy of Undetermined Significance in a Korean Elderly Urban Cohort
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2015;47(2):5-220 Original Article http://dx.doi.org/10.4143/crt.2013.262 Open Access Five-Year Follow-up Study of Monoclonal Gammopathy of Undetermined
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL GENERAL FORMS AND GUIDELINES MYELOMA FORMS CHAPTER 16D REVISED: SEPTEMBER 2016
MYELOMA FORMS The guidelines and figures below are specific to Myeloma studies. The information in this manual does NOT represent a complete set of required forms for any myeloma study. Please refer to
More informationYour Test Results. Understanding. Multiple Myeloma Cancer of the Bone Marrow. A publication of the International Myeloma Foundation
Multiple Myeloma Cancer of the Bone Marrow Understanding Your Test Results U-YTR_EN_2018_j1 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800.452.CURE (USA & Canada) 818.487.7455
More informationQ1 What is your occupation/role? (select all that apply) Answered: 310 Skipped: 4 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Q1 What is your occupation/role? (select all that apply) Answered: 310 Skipped: 4 ANSWER CHOICES Pathologist Total Respondents: 310 Pathologist Physician (non-radiolo... Medical Director Technologist/Te
More informationDiagnosis of multiple myeloma (MM) requires the examination
TECHNIQUES FOR EVALUATION OF PATIENTS WITH MULTIPLE MYELOMA New Tools for Diagnosis and Monitoring of Multiple Myeloma Jesús F. San-Miguel, MD, PhD, Bruno Paiva, PhD, and Norma C. Gutiérrez, MD, PhD OVERVIEW
More informationepoint.edu.vn page 2 / 5
SERUM FREE LIGHT CHAIN ANALYSIS FOR THE DIAGNOSIS MANAGEMENT AND PROGNOSIS OF PLASMA CELL DYSCRASIAS FUTURE RESEARCH NEEDS FUTURE RESEARCH NEEDS PAPER NUMBER 23 page 1 / 5 page 2 / 5 serum free light chain
More informationLeukemia (2008), 1 10 & 2008 Macmillan Publishers Limited All rights reserved /08 $
REVIEW (2008), 1 10 & 2008 Macmillan Publishers Limited All rights reserved 0887-6924/08 $32.00 www.nature.com/leu for serum-free light chain analysis in multiple myeloma and related disorders A Dispenzieri
More informationRelatively Restricted Migration of Polyclonal IgG4 May Mimic a Monoclonal Gammopathy in IgG4-Related Disease
Relatively Restricted Migration of Polyclonal 4 May Mimic a Monoclonal Gammopathy in 4-Related Disease Joannes F. M. Jacobs, MD, PhD, 1,2 Renate G. van der Molen, PhD, 1 and David F. Keren, MD, PhD 3 From
More informationMonitoring IgA Multiple Myeloma: Immunoglobulin Heavy/Light Chain Assays
Clinical Chemistry 61:2 360 367 (2015) Clinical Immunology Monitoring IgA Multiple Myeloma: Immunoglobulin Heavy/Light Chain Assays Jerry A. Katzmann, 1,2* Maria A.V. Willrich, 1 Mindy C. Kohlhagen, 1
More informationYour Test Results. Understanding. Improving Lives Finding the Cure. Multiple Myeloma Cancer of the Bone Marrow
Multiple Myeloma Cancer of the Bone Marrow Understanding Your Test Results u-ytr_en_2017_h4 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada)
More informationMinimal Residual Disease assessment in Multiple Myeloma by Next-Generation Sequencing
Minimal Residual Disease assessment in Multiple Myeloma by Next-Generation Sequencing Prof Hervé AVET-LOISEAU, : MD, PhD Institut Universitaire du Cancer Toulouse, France MRD Meta-Analysis in Myeloma Nikhil
More informationSignificance of Abnormal Protein Bands in Patients with Multiple Myeloma following Autologous Stem Cell Transplantation
Original Article Significance of Abnormal Protein Bands in Patients with Multiple Myeloma following Autologous Stem Cell Transplantation Sara L. Hall, 1 Jill Tate, 2 Devinder Gill, 1,3 *Peter Mollee 1,3
More informationElevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-hodgkin lymphoma
Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-hodgkin lymphoma AJH Thomas E. Witzig, 1 * Matthew J. Maurer, 2 Thomas M. Habermann,
More informationClinico hematological profile of multiple myeloma in tertiary care Hospital, Pune
Original article Clinico hematological profile of multiple myeloma in tertiary care Hospital, Pune Dr. Sagale MS, Dr. Dangmali DP, Dr. Rane SR, Dr. Kulkarni KK, Dr. Puranik SC Department of Pathology,
More information